The price of F-star Therapeutics Inc. (NASDAQ:FSTX) shares last traded on Wall Street unchanged to $7.12.
Based on available information, 2 analysts follow F-star Therapeutics Inc. (NASDAQ:FSTX). The consensus rating among analysts is ‘Hold’. As we calculate the median target price by taking the range between a high of $7.00 and a low of $7.00, we find $7.00. Given the previous closing price of $7.12, this indicates a potential downside of -1.69 percent. FSTX stock price is now 30.60% away from the 50-day moving average and 29.48% away from the 200-day moving average. The market capitalization of the company currently stands at $161.98M.
Do You Know The Best Place To Find Gains In Volatile Markets?
In today's chaotic marketplace, the biggest gains will come from some currently-small companies that pass by older, larger businesses still stuck in a pre-pandemic world. The trick is figuring out which small caps will be tomorrow's winners. That's why StockWire News has put together a special Wealth Building Report, highlighting 3 small cap stocks set to soar in 2023.
Click here for full details and to join for free.
Sponsored
Among analysts, 2 rate the stock a hold while 0 rate it a buy. Brokers who have rated the stock have averaged $7.00 as their price target over the next twelve months.
With the price target reduced from $35 to $7, H.C. Wainwright Downgraded its rating from Buy to Neutral for F-star Therapeutics Inc. (NASDAQ: FSTX).
A total of 2.40% of the company’s stock is owned by insiders.
There have been several recent changes in the stakes of large investors in FSTX stock. A new stake in F-star Therapeutics Inc. shares was purchased by ARMISTICE CAPITAL, LLC during the first quarter worth $7,120,000. TRIUM CAPITAL LLP invested $4,840,000 in shares of FSTX during the first quarter. In the first quarter, WEISS ASSET MANAGEMENT LP acquired a new stake in F-star Therapeutics Inc. valued at approximately $3,903,000. QUINN OPPORTUNITY PARTNERS LLC acquired a new stake in FSTX for approximately $1,280,000. VAZIRANI ASSET MANAGEMENT LLC purchased a new stake in FSTX valued at around $890,000 in the second quarter. In total, there are 66 active investors with 46.10% ownership of the company’s stock.
A candlestick chart of F-star Therapeutics Inc. (NASDAQ: FSTX) showed a price of $7.11 on Wednesday morning. During the past 12 months, F-star Therapeutics Inc. has had a low of $2.07 and a high of $7.12. As of last week, the company has a debt-to-equity ratio of 0.17, a current ratio of 3.40, and a quick ratio of 3.40. The fifty day moving average price for FSTX is $5.45 and a two-hundred day moving average price translates $5.50 for the stock.
The latest earnings results from F-star Therapeutics Inc. (NASDAQ: FSTX) was released for Sep, 2022. According to the Biotechnology Company, earnings per share came in at -$0.84, missing analysts’ expectations of -$0.79 by -0.05. This compares to -$0.52 EPS in the same period last year. The company reported revenue of $1.12 million for the quarter, compared to $0.75 million a year earlier. Comparatively to last year’s same quarter, the company’s quarterly revenue rose 49.8 percent.
F-star Therapeutics Inc.(FSTX) Company Profile
F-star Therapeutics, Inc., a clinical-stage biopharmaceutical company, develops tetravalent bispecific antibodies for cancer therapy. Its medicines are used in immuno-oncology treatments. The company’s principal product candidate is FS118 and is being evaluated in a proof-of-concept Phase 2 trial in PD-1/PD-L1 acquired resistance head and neck cancer patients. It is also developing first-in-human clinical study of FS222, a bispecific antibody that is in Phase 1 clinical trial targeting the costimulatory CD137 receptor and the inhibitory PD-L1 ligand. In addition, the company is also evaluating FS120 and SB 11285 for patients with advanced cancers, which are under Phase 1 clinical trials. F-star Therapeutics, Inc. was incorporated in 2002 and is headquartered in Cambridge, the United Kingdom.
